Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
26.30
+5.86 (28.67%)
Oct 8, 2025, 2:13 PM EDT - Market open
Intellia Therapeutics Employees
Intellia Therapeutics had 403 employees as of December 31, 2024. The number of employees decreased by 123 or -23.38% compared to the previous year.
Employees
403
Change (1Y)
-123
Growth (1Y)
-23.38%
Revenue / Employee
$131,159
Profits / Employee
-$1,191,548
Market Cap
2.82B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 403 | -123 | -23.38% |
Dec 31, 2023 | 526 | -72 | -12.04% |
Dec 31, 2022 | 598 | 113 | 23.30% |
Dec 31, 2021 | 485 | 173 | 55.45% |
Dec 31, 2020 | 312 | 42 | 15.56% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NTLA News
- 4 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug - Benzinga
- 13 days ago - Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - GlobeNewsWire
- 18 days ago - Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis - Seeking Alpha
- 20 days ago - Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema - GlobeNewsWire
- 5 weeks ago - Why big players are pouring millions in THIS biotech stock - Invezz
- 7 weeks ago - Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade) - Seeking Alpha
- 2 months ago - Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript - Seeking Alpha